NanoViricides, Inc. (NNVC)Healthcare | Biotechnology | Shelton, United States | NYSE American
1.31 USD
-0.01
(-0.758%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 1.31 |
Hot Take ↕ | Oct. 10, 2026, 2:17 a.m. EDT
The investment case here is defined by a stark disconnect between the company's deteriorating fundamentals and the aggressive speculative positioning in the options market. Fundamentally, the business is in severe distress: the stock has lost 95.8% of its value over the last nine years, trailing earnings are negative, and free cash flow is burning through reserves. The lack of a dividend and negative return on equity confirms there is no income floor or capital preservation mechanism. While the analyst consensus suggests a 'strong buy' with a $6.00 target, this appears to be a reaction to the specific narrative of the Ebola outbreak and the company's pipeline assets rather than a reflection of robust financial health. The options data reveals the true nature of the trade: traders are buying deep out-of-the-money calls, betting on a sudden, explosive price surge driven by clinical trial results or regulatory approvals, while ignoring the multi-year structural decline. This is a high-risk, binary event play where the odds of success are low given the cash burn, but the potential reward is unlimited if the catalyst hits. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.139638 |
| MSTL | 0.205534 |
| AutoETS | 0.207966 |
| AutoTheta | 0.211698 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 28.34 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.255 |
| Excess Kurtosis | -0.49 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 33,437,748 |
| Forward P/E | -3.74 |
| Beta | 1.79 |
| Website | https://www.nanoviricides.com |
As of Oct. 10, 2026, 2:17 a.m. EDT: Speculators are overwhelmingly positioned for upside, evidenced by massive open interest in out-of-the-money calls (strikes $5.00 and $7.50) compared to negligible put activity. This indicates a speculative bet on a binary event or a sharp rally rather than a hedging strategy against downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.08333331 |
| Address1 | 1 Controls Drive |
| All Time High | 262.5 |
| All Time Low | 0.85 |
| Ask | 1.31 |
| Ask Size | 300 |
| Average Daily Volume10 Day | 300,680 |
| Average Daily Volume3 Month | 425,942 |
| Average Volume | 425,942 |
| Average Volume10Days | 300,680 |
| Beta | 1.791 |
| Bid | 1.3 |
| Bid Size | 200 |
| Book Value | 0.377 |
| City | Shelton |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.31 |
| Current Ratio | 2.656 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.34 |
| Day Low | 1.28 |
| Display Name | NanoViricides |
| Dividend Date | 1,569,283,200 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,747,339,200 |
| Earnings Timestamp Start | 1,747,339,200 |
| Ebitda | -7,781,075 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.971 |
| Enterprise Value | 30,898,900 |
| Eps Current Year | -0.35 |
| Eps Forward | -0.35 |
| Eps Trailing Twelve Months | -0.41 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.3124 |
| Fifty Day Average Change | -0.0024000406 |
| Fifty Day Average Change Percent | -0.0018287417 |
| Fifty Two Week Change Percent | -8.333331 |
| Fifty Two Week High | 2.23 |
| Fifty Two Week High Change | -0.9200001 |
| Fifty Two Week High Change Percent | -0.41255608 |
| Fifty Two Week Low | 0.85 |
| Fifty Two Week Low Change | 0.45999992 |
| Fifty Two Week Low Change Percent | 0.5411764 |
| Fifty Two Week Range | 0.85 - 2.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,130,333,400,000 |
| Float Shares | 24,924,652 |
| Forward Eps | -0.35 |
| Forward P E | -3.742857 |
| Free Cashflow | -4,754,714 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 7 |
| Fullday Change | 0.099699974 |
| Fullday Change Percent | 7.7890606 |
| Fullday Price | 1.31 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02487 |
| Held Percent Institutions | 0.09292 |
| Implied Shares Outstanding | 25,525,000 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,782,777,600 |
| Last Split Date | 1,569,283,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. |
| Long Name | NanoViricides, Inc. |
| Market | us_market |
| Market Cap | 33,437,748 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_22594191 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -8,218,509 |
| Next Fiscal Year End | 1,814,313,600 |
| Non Diluted Market Cap | 38,546,303 |
| Number Of Analyst Opinions | 2 |
| Open | 1.32 |
| Operating Cashflow | -7,696,015 |
| Operating Margins | 0.0 |
| Phone | 203 937 6137 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.31 |
| Post Market Time | 1,792,014,487 |
| Previous Close | 1.32 |
| Price Eps Current Year | -3.742857 |
| Price Hint | 4 |
| Price To Book | 3.4748008 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.347 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.01000011 |
| Regular Market Change Percent | -0.75758404 |
| Regular Market Day High | 1.34 |
| Regular Market Day Low | 1.28 |
| Regular Market Day Range | 1.28 - 1.34 |
| Regular Market Open | 1.32 |
| Regular Market Previous Close | 1.32 |
| Regular Market Price | 1.31 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 150,161 |
| Return On Assets | -0.55531 |
| Return On Equity | -1.0146 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 25,525,000 |
| Shares Percent Shares Out | 0.0363 |
| Shares Short | 925,462 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 646,145 |
| Short Name | NanoViricides, Inc. |
| Short Percent Of Float | 0.037100002 |
| Short Ratio | 1.4 |
| Source Interval | 15 |
| State | CT |
| Symbol | NNVC |
| Target High Price | 6.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 6.0 |
| Target Median Price | 6.0 |
| Total Cash | 2,794,110 |
| Total Cash Per Share | 0.109 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.2759 |
| Two Hundred Day Average Change | 0.034099936 |
| Two Hundred Day Average Change Percent | 0.026726183 |
| Type Disp | Equity |
| Volume | 150,161 |
| Website | https://www.nanoviricides.com |
| Zip | 6,484 |